Pfizer Payout Strains: Income Investors Face Hard Truth
Pfizer paid more in dividends than its free cash flow in 2025, a warning sign for income investors facing hard realit...
When time is of the essence, knowing ways to get emergency cash quickly can make a difference. Explore your options.
23,900 articlesPfizer paid more in dividends than its free cash flow in 2025, a warning sign for income investors facing hard realit...
Investing often favors flashy stories, but some of the strongest returns come from straightforward, reliable business...
As investors chase high dividend yields, AT&T is quietly delivering accelerating free cash flow while Verizon faces a...
Star Bulk reported a solid Q1 2026, reflecting steady demand for commodities and a modern fleet. This article unpacks...
CoreWeave is expanding fast on the AI cloud frontier, but heavy borrowing and rising interest expenses are pulling th...
Fuel shortages and rolling blackouts push Cuba toward a tipping point as sanctions tighten Venezuelan oil shipments. ...
A strong first quarter and solid cash generation helped CVS Health's shares spark on Wednesday. This guide breaks dow...
Analysts outline a two-year price path for Amazon, balancing outsized AWS growth and ad revenue against hefty capital...
Alphabet has overtaken its peers to become the most profitable U.S. tech giant as AI and cloud demand drive stronger ...
Long-term investors chase multibagger dreams. This article explores a high-potential biotech setup with 26 late-stage...
The VanEck PFXF ETF focuses on non-financial preferred securities, offering a ~6.7% yield. But investors must watch c...
A new payment option is pushing into the spotlight without fanfare. Pay-by-bank quietly gaining ground challenges the...